Skip to main content

NIDDK Seeks Applicants to Expand Drug Induced Liver Injury Network

NEW YORK (GenomeWeb News) – The National Institute of Diabetes and Digestive and Kidney Diseases plans this fall to issue RFAs that will extend a program it started in 2003 that uses various genomics methods to study liver diseases caused by adverse drug reactions.
 
NIDDK did not say how much funding it intends to use to support the Drug Induced Liver Injury Network, which is a seven-center pharmacogenomic effort that is a close collaborator of the Serious Adverse Events Consortium. The SAEC is a pharmaceutical industry-led effort to find out what causes drug-related adverse events that can impede pharmaceutical development.
 
NIDDK also said it plans to expand the DILIN to include an eighth center. Current members include the University of California at San Francisco, the University of Michigan, Indiana University, the University of North Carolina at Chapel Hill, Duke University, the University of Connecticut, and the National Institutes of Health.
 
The research will focus on pharmacogenomic analysis and bioinformatics development for finding phenotype/genotype associations, and biomarker validation studies, NIDDK said. The scientists also will conduct research in demographic and geographic distribution.
 
Information about where to send inquiries can be found here.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.